The strong Phase 3 data positions envudeucitinib as a leading oral TYK2 inhibitor in psoriasis, with NDA submission expected in 2H 2026. The cash runway into Q4 2027 supports continued development, including the upcoming SLE readout in 3Q 2026, which could further validate the 'pipeline-in-a-pill' strategy. Traders should monitor AAD 2026 data presentation and KOL reaction.
Price Chart
Executive Summary
Alumis reported positive Phase 3 results for envudeucitinib in moderate-to-severe plaque psoriasis, demonstrating high skin clearance rates and a favorable safety profile. The company also announced it raised $345.1 million in a public offering and has sufficient cash to fund operations into Q4 2027. Despite strong clinical progress, the company reported a net loss of $243.3 million for 2025, driven by increased R&D and merger-related expenses.
Key Financial Metrics
Key Facts
- Positive Phase 3 topline results for envudeucitinib in plaque psoriasis with ~65% achieving PASI 90 and >40% achieving PASI 100 at Week 24
- Plan to submit NDA for envudeucitinib in psoriasis in 2H 2026
- Raised $345.1 million in gross proceeds from an upsized public offering in January 2026
- Cash, cash equivalents, and marketable securities totaled $308.5 million as of December 31, 2025
- Net loss was $243.3 million for 2025, improved from $294.2 million in 2024
- Potentially pivotal Phase 2b SLE data expected in 3Q 2026
Financial Impact
Net loss decreased by $50.9 million YoY despite higher R&D spend; $345.1 million capital raise strengthens balance sheet
Risk Factors
- Clinical failure or safety issues in upcoming SLE trial could undermine 'pipeline-in-a-pill' thesis
- Dilution from recent offering of 20.3M shares (~17% of pre-offering float assuming ~120M shares outstanding)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259420 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 6w ago | Insider Buy | $9.90 $9.18 | ▼ −7.27% | ▼ −8.13% | $6.51 (−34.24%) |
Sep 1, 2026 8w ago | 8-K | $9.47 $10.35 | ▲ +9.29% | ▲ +8.85% | $6.51 (−31.26%) |
Aug 15, 2026 10w ago | Institutional Cluster | $25.50 $24.88 | ▼ −2.43% | ▼ −1.76% | $6.51 (−74.47%) |
Aug 10, 2026 11w ago | 8-K | $25.37 $25.55 | ▲ +0.71% | ▲ +0.46% | $6.51 (−74.34%) |
Aug 5, 2026 11w ago | Insider Cluster | $27.80 $27.60 | ▼ −0.72% | ▼ −1.33% | $6.51 (−76.58%) |
Aug 5, 2026 11w ago | Insider Cluster | $27.80 $27.60 | ▼ −0.72% | ▼ −1.33% | $6.51 (−76.58%) |
Jun 29, 2026 17w ago | 8-K | $27.14 $28.14 | ▲ +3.68% | ▲ +2.91% | $6.51 (−76.01%) |
Jun 11, 2026 19w ago | Institutional Cluster | $20.90 $24.15 | ▲ +15.55% | ▲ +15.01% | $6.51 (−68.85%) |
May 18, 2026 23w ago | DEFA14A | $21.53 $22.04 | ▲ +2.39% | ▲ +1.35% | $6.51 (−69.76%) |
Mar 28, 2026 30w ago | Press Release | $20.21 $22.03 | ▲ +9.01% | ▲ +6.11% | $6.51 (−67.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers